Belite Bio, Inc (BLTE)
NEGATIVE基本面
~26
价格
$162.31
市值
$6.44B
第一部分 · 这家公司值多少
概览
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
可用财务数据有限（33% 的指标）。评分可能无法准确反映该公司的基本面。
资产负债表与流动性
营收
0
截至2025/12/31的财政年度
净利润
$-78M
截至2025/12/31的财政年度
自由现金流
-
股东权益合计
$777M
负债合计
0
流动比率
33.56
利息覆盖率
-
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$214.00
当前价格
$162.31
安全边际
+24.2%
公允价值区间
$203.30 - $224.70
估算方法
估值指标
市盈率（P/E）
-
ROE
-22.1%
市净率（P/B）
8.11
P/FCF
-
毛利率
0.0%
ROIC
-
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
基本面分析标准
通过（3）
- Price CAGR 52.03%
- Current Ratio
- Analyst Consensus 93% Buy
未通过（6）
- Gross Margin 0.0%
- P/B Ratio 8.11
- DCF valuation (Unknown)
- ROE -26.9%
- Earnings Surprise avg -19.7%
- Piotroski F-Score 0/9
不可用（18）
- EPS data insufficient
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
- Net Margin Trend (invalid data)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在回购股份，对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | 47 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | 41 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 59 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 56 |
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for BLTE, sourced from Markets Gazette.
- 3/3/2026NEUTRALBelite Bio (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio (BLTE) investors are awaiting crucial details following the announcement of the Q4 2025 earnings call transcript. Although the event was reported, the actual content of the transcript is not yet available. This lack of information prevents analysts and investors from assessing the company's financial performance, future outlook, or any significant announcements that could impact the stock's value. Transparency is key for the market, and the absence of concrete data keeps the stock in a phase of uncertainty, with operators eagerly awaiting details to formulate forecasts and make informed decisions.
via Markets Gazette